Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 12/20 | 0.62 |
| ▸ | CHRNA10 | Q9GZZ6 | 12/20 | 0.62 |
| ▸ | CHRNA9 | Q9UGM1 | 12/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3310844 | 0.99 | CHRNA7 (0.63) | CHRNA7CHRNA10CHRNA9CHRNB2CHRNB4 | |
| SCHEMBL13334255 | 0.86 | CHRNA7 (0.58) | CHRNA7CHRNA10CHRNA9CHRNB2CHRNB4 | |
| Bromide SCHEMBL3312025 | 0.85 | CHRNA7 (0.59) | CHRNA7CHRNA10CHRNA9CHRNB2CHRNB4 | |
| SCHEMBL13334233 | 0.84 | CHRNA7 (0.67) | CHRNA7CHRNA10CHRNA9CHRNB2CHRNB4 | |
| SCHEMBL13334215 | 0.84 | CHRNA7 (0.67) | CHRNA7CHRNA10CHRNA9CHRNB2CHRNB4 | |
| SCHEMBL13334237 | 0.83 | CHRNA7 (0.84) | CHRNA7CHRNA10CHRNA9CHRNB2CHRNB4 | |
| Bromide SCHEMBL3313506 | 0.83 | CHRNA7 (0.68) | CHRNA7CHRNA10CHRNA9CHRNB2CHRNB4 | |
| SCHEMBL12638080 | 0.83 | CHRNA7 (0.57) | CHRNA7CHRNA10CHRNA9CHRNB2CHRNB4 | |
| Bromide SCHEMBL3312133 | 0.83 | CHRNA7 (0.68) | CHRNA7CHRNA10CHRNA9CHRNB2CHRNB4 | |
| SCHEMBL13334222 | 0.83 | CHRNA7 (0.61) | CHRNA7CHRNA10CHRNA9CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550753-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIV KENTUCKY RES FOUND (US) | 2014-12-18 | — | — | US | disclosed |
| US-8846937-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA4, CHRNA5 | CHRNA7 8/4885CHRNA10 4/4885CHRNA9 13/4885 |
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA4, CHRNA5 | CHRNA7 8/4885CHRNA10 4/4885CHRNA9 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.